Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis is under clinical development by HAL Allergy and currently in Phase II for Allergic Rhinitis. According to GlobalData, Phase II drugs for Allergic Rhinitis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis overview
Sublivac fix Phleum pratense is under development for the treatment of grass pollen allergy in patients with allergic rhinitis, and rhinoconjunctivitis. The drug candidate is administered through sublingual route. The drug candidate is a cluster-allergoid extract of Phleum pratense pollen.
HAL Allergy overview
HAL Allergy (HAL) is a biopharmaceutical company that develops, manufactures and sells allergy vaccines and diagnostics for allergens. The company’s product portfolio include puretHAL, venomenHAL and sublivac. It also offers diagnostic products such as provocation tests, patch tests and skin prick tests. HAL provides contract manufacturing services. The company offers oral preparation for allergens such as quercus robur, fraxinus excelsior, fagus silvatica, urtica dioica, plantago lanceolata, artemisia vulgaris, ambrosia, aspergillus and alternaria. It operates through its subsidiaries in Germany, Spain, Italy, Poland, Austria and Benelux. The company distributes its products through distribution partners across Europe. HAL is headquartered in Leiden, the Netherlands.
For a complete picture of Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
